<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345046</url>
  </required_header>
  <id_info>
    <org_study_id>0201-28</org_study_id>
    <nct_id>NCT00345046</nct_id>
  </id_info>
  <brief_title>A Comparison of Three Different Formulations of Prednisolone Acetate 1%</brief_title>
  <official_title>A Comparison of Three Different Formulations of Topical Prednisolone Acetate 1% for Control of Post Glaucoma and/or Cataract Surgery Inflammation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Generic prednisolone acetate 1% is less effective than Pred Forte 1% or Econopred Plus 1%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall Study Design:

      Structure:

      This is a randomized, double-masked prospective study. The study medications will be masked
      and randomized by the outpatient pharmacy at Indiana University Hospital.

      Duration:

      Treatment duration: The duration of each subject's participation will be for up to 2 months
      after surgery. One hundred and two subjects will be enrolled over a twelve-month time span.

      Controls:

      Examiner, staff, and subjects are masked. Parallel group comparison.

      Dosage/Dose Regimen/Instructions:

      Subjects scheduled for glaucoma and/or cataract surgery will be recruited. Subjects may not
      be currently on any steroid or ophthalmic non-steroidal anti-inflammatory (NSAID) therapy for
      a minimum of 6 weeks prior to surgery. Subjects will be randomized to receive a dose of Pred
      Forte 1% (Allergan), Econopred Plus 1% (Alcon) or prednisolone acetate 1% (Falcon) four times
      a day starting immediately after finishing the surgery for two weeks, then twice a day for
      two more weeks. After 1 month of therapy subjects will stop or continue steroid treatment
      based on clinical findings. No other subconjunctival steroid or ointment will be used
      intra-operatively or post-operatively. The eye drop will be instilled per labeling
      instructions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Flare at Resolution</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Glaucoma</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Pred Forte 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EconoPred Plus 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone Acetate 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pred Forte</intervention_name>
    <description>Four drops daily decreasing to once daily over four weeks.</description>
    <arm_group_label>Pred Forte 1%</arm_group_label>
    <other_name>Econopred Plus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EconoPred Plus</intervention_name>
    <description>Prednisolone Acetate four times daily decreasing to once daily over four weeks.</description>
    <arm_group_label>EconoPred Plus 1%</arm_group_label>
    <other_name>Pred Forte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate</intervention_name>
    <description>Dosed four times daily decreasing to once daily over four weeks.</description>
    <arm_group_label>Prednisolone Acetate 1%</arm_group_label>
    <other_name>Pred Forte</other_name>
    <other_name>EconoPred Plus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be willing and able to provide written informed consent.

          -  Be able and willing to follow instructions on the use of the study medication and
             likely to complete the entire course of the study.

          -  Be male or female of any race at least 18 years of age.

          -  Have visually significant cataract or medically uncontrolled glaucoma for which they
             have elected to undergo surgery.

        Exclusion Criteria:

          -  Contraindication to use of corticosteroids.

          -  Ocular disease other than glaucoma or ocular hypertension that would interfere with
             study parameters (such as: uveitis, ocular infection, or severe dry eye). Subjects
             with mild chronic blepharitis, age-related macular degeneration and background
             diabetic retinopathy may be enrolled at the discretion of the investigator.

          -  Laser or any other intraocular surgery within the past three months.

          -  Require use of ocular NSAID or systemic steroids.

          -  Have known allergy or sensitivity to the study medications or their components

          -  Have corneal abnormalities that would interfere with the ability to obtain an adequate
             laser flare measurement.

          -  Be concurrently enrolled in an investigational drug or device study or participation
             within the last 30 days in any investigational drug or device study.

          -  Be pregnant, nursing, planning a pregnancy, or be of childbearing potential and not
             using a reliable form of contraception (a woman is considered of childbearing
             potential unless she is postmenopausal, has had a uterus and/or both ovaries removed,
             or has had a bilateral tubal ligation).

          -  Have a situation or condition that in the investigator's opinion may put the subject
             at significant risk, may confound the study results, or may interfere significantly
             with participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis B Cantor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IUPUI/Clarian</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IU Eye at Carmel</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.fda.gov/cder/ob/default.htm</url>
    <description>Electronic Orange Book</description>
  </link>
  <reference>
    <citation>Cantor LB. Ophthalmic generic drug approval process: implications for efficacy and safety. J Glaucoma. 1997 Oct;6(5):344-9. Review.</citation>
    <PMID>9327353</PMID>
  </reference>
  <reference>
    <citation>Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol. 1987 Oct;123(10):1312-4.</citation>
    <PMID>3662563</PMID>
  </reference>
  <reference>
    <citation>Olsen EA. A double-blind controlled comparison of generic and trade-name topical steroids using the vasoconstriction assay. Arch Dermatol. 1991 Feb;127(2):197-201.</citation>
    <PMID>1990984</PMID>
  </reference>
  <reference>
    <citation>Casale TB, Azzam SM, Miller RE, Oren J. Demonstration of therapeutic equivalence of generic and innovator beclomethasone in seasonal allergic rhinitis. SAR Study Group. Ann Allergy Asthma Immunol. 1999 May;82(5):435-41.</citation>
    <PMID>10353573</PMID>
  </reference>
  <reference>
    <citation>Nell H, Louw CM, Cyster H, Williams Z, Bardin PG, Joubert JR. Therapeutic equivalence study of two formulations (innovator v. generic) of beclomethasone dipropionate in adult asthmatic patients. S Afr Med J. 2001 Jan;91(1):51-6.</citation>
    <PMID>11236299</PMID>
  </reference>
  <reference>
    <citation>Apt L, Henrick A, Silverman LM. Patient compliance with use of topical ophthalmic corticosteroid suspensions. Am J Ophthalmol. 1979 Feb;87(2):210-4.</citation>
    <PMID>434075</PMID>
  </reference>
  <reference>
    <citation>Hille K, Hans J, Manderscheid T, Spang S, Ruprecht KW. [Laser flare in combined cataract and glaucoma surgery]. Ophthalmologe. 2001 Jan;98(1):47-53. German.</citation>
    <PMID>11220271</PMID>
  </reference>
  <reference>
    <citation>Shah SM, Spalton DJ, Taylor JC. Correlations between laser flare measurements and anterior chamber protein concentrations. Invest Ophthalmol Vis Sci. 1992 Sep;33(10):2878-84.</citation>
    <PMID>1526738</PMID>
  </reference>
  <reference>
    <citation>Fiscella RG, Gutta R, Goldstein DB, Viana MAG. Comparison of PredForte Brand to generic Prednisolone acette and loteprednol etabonate (lotemax) in a Rabbit Model of Inflammation. American Academy of Ophthalmology 2001 Annual Meeting, Poster 73 Session 2001.</citation>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2006</study_first_submitted>
  <study_first_submitted_qc>June 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2006</study_first_posted>
  <results_first_submitted>December 24, 2013</results_first_submitted>
  <results_first_submitted_qc>March 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Cataract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period Feb 2005 - Jun 2008 Subjects were recruited from surgical schedule.</recruitment_details>
      <pre_assignment_details>One subject was disqualified due to previous laser treatment. One subject did not receive study medication therefore was discontinued from study participation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pred Forte 1%</title>
          <description>Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.</description>
        </group>
        <group group_id="P2">
          <title>EconPred Plus 1%</title>
          <description>EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.</description>
        </group>
        <group group_id="P3">
          <title>Prednisolone Acetate 1%</title>
          <description>Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pred Forte</title>
          <description>Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.
Pred Forte: Four drops daily decreasing to once daily over four weeks.</description>
        </group>
        <group group_id="B2">
          <title>EconoPred Plus</title>
          <description>EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.
EconoPred Plus: Prednisolone Acetate four times daily decreasing to once daily over four weeks.</description>
        </group>
        <group group_id="B3">
          <title>Prednisolone Acetate</title>
          <description>Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.
Prednisolone Acetate: Dosed four times daily decreasing to once daily over four weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="15.2"/>
                    <measurement group_id="B2" value="68.3" spread="13.0"/>
                    <measurement group_id="B3" value="65.7" spread="16.6"/>
                    <measurement group_id="B4" value="66.5" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Flare at Resolution</title>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pred Forte 1%</title>
            <description>Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Econo Pred Plus 1%</title>
            <description>EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.
EconoPred Plus: Prednisolone Acetate four times daily decreasing to once daily over four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Predisolone Acetate 1%</title>
            <description>Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.
Prednisolone Acetate: Dosed four times daily decreasing to once daily over four weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Flare at Resolution</title>
          <units>Percent change in flare</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" spread="15.2"/>
                    <measurement group_id="O2" value="68.3" spread="13.0"/>
                    <measurement group_id="O3" value="65.7" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pred Forte 1%</title>
          <description>Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.
Pred Forte: Four drops daily decreasing to once daily over four weeks.</description>
        </group>
        <group group_id="E2">
          <title>EconoPred Plus 1%</title>
          <description>EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.
EconoPred Plus: Prednisolone Acetate four times daily decreasing to once daily over four weeks.</description>
        </group>
        <group group_id="E3">
          <title>Prednisolone Acetate 1%</title>
          <description>Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.
Prednisolone Acetate: Dosed four times daily decreasing to once daily over four weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Louis B. Cantor</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-278-2651</phone>
      <email>lcantor@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

